SUBSTIPHARM in the news

Medigen Vaccine Biologics Corp. and Substipharm Biologics secured marketing authorization for the first Enterovirus A71 vaccine in Vietnam to combat pediatric HFMD outbreaks.

DHL Supply Chain is partnering with Substipharm to manage the logistics and distribution of Aspégic and Kardégic brands across France.

DHL Supply Chain is managing the full logistics cycle for Substipharm's newly acquired Aspégic and Kardégic medicine brands in France.

Substipharm Biologics and MVC have secured Vietnamese approval for Envacgen, the first EV-A71 vaccine to combat hand, foot, and mouth disease in the region.

Medigen and Substipharm have secured Vietnam's first marketing authorization for an EV-A71 vaccine to combat local pediatric HFMD outbreaks.

MVC and Substipharm Biologics obtained marketing authorization for the EV-A71 vaccine, ENVACGEN®, in Vietnam, aiming to meet regional demand for pediatric health.

SUBSTIPHARM is recalling a batch of its Bifonazole 1% cream due to stability issues with active ingredients, requiring a precautionary withdrawal from pharmacies and establishments.

Substipharm has obtained the marketing authorization for KIPOS®, a high-dose vitamin D3 soft capsule, and announced its return to stock.

SUBSTIPHARM launched Clindamycine SUBSTIPHARM 300 mg, a generic equivalent of DALACINE, indicated for various bacterial infections.

VNVC and Substipharm Biologics are partnering to launch an EV71 vaccine in Vietnam to combat severe hand, foot, and mouth disease outbreaks in children.

Sanofi is selling its Amilly plant to Astrea Pharma while Substipharm takes over the marketing rights for Aspegic and Kardegic.

VNVC and Substipharm Biologics partnered to bring a Hand, Foot, and Mouth Disease vaccine to Vietnam, aiming to combat the severe EV71 strain and reduce its public health impact.

Substipharm Biologics SA is partnering with VNVC to introduce a hand, foot, and mouth disease vaccine in Vietnam.

VNVC Immunization Center System and Swiss company Substipharm Biologics SA are collaborating to introduce an EV71 hand, foot, and mouth disease vaccine to Vietnam.

VNVC and Substipharm Biologics are partnering to distribute a new hand-foot-mouth disease vaccine in Vietnam to address urgent public health needs and high mortality rates in children.

Substipharm Biologics is partnering with Medigen to distribute the ENVACGEN® enterovirus vaccine across Vietnam and several other Southeast Asian countries.

A strategic partnership expansion between Zuellig Pharma and Substipharm Biologics aims to distribute life-saving vaccines for Japanese Encephalitis across diverse Asian markets.

Zuellig Pharma is partnering with Substipharm Biologics to market and distribute the IMOJEV Japanese encephalitis vaccine across nine Asian markets.

A commercial partnership between Zuellig Pharma and Substipharm Biologics will expand the distribution and marketing of the IMOJEV Japanese encephalitis vaccine across nine Asian markets.